The influence of chronic cerebral hypoperfusion on cognitive function and amyloid β metabolism in app overexpressing mice

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Yamada, Mahito ^a   Ihara, Masafumi ^a   Okamoto, Yoko ^a   Maki, Takakuni ^a   Washida, Kazuo ^a   Kitamura, Akihiro ^a   Hase, Yoshiki ^a   Ito, Hidefumi ^a   Takao, Keizo ^b   Miyakawa, Tsuyoshi ^c   Kalaria, Raj N ^d   Tomimoto, Hidekazu ^e   Takahashi, Ryosuke ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NationalInstitute for Physiological Sciences   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e MIE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ARTICLE; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; CELL DENSITY; COGNITION; COGNITIVE DEFECT; COMMON CAROTID ARTERY; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HIPPOCAMPUS; HISTOPATHOLOGY; LEARNING DISORDER; MAZE TEST; MOUSE; NOCICEPTION; NONHUMAN; PROTEIN EXPRESSION; REFERENCE MEMORY; SURVIVAL RATE; ANIMAL; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CAROTID STENOSIS; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; COGNITION DISORDERS; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; NEURONS;

EID: 79551551961     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016567     Document Type: Article

References (38)

1. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, et al. (2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37: 2220-2241.
2. Kalaria R (2002) Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 203-204: 29-34.
3. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33: 1152-1162.
4. Kalaria RN (1996) Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 72: 193-214.
5. Kitaguchi H, Ihara M, Saiki H, Takahashi R, Tomimoto H (2007) Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease. Neurosci Lett 417: 128-131.
6. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol 115: 599-609.
7. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28: 202-208.
8. Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, et al. (2010) A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 41: 1278-1284.
9. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, et al. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817.
10. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69: 2197-2204.
11. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, et al. (2009) Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6: e1000180.
12. Fotuhi M, Hachinski V, Whitehouse PJ (2009) Changing perspectives regarding late-life dementia. Nat Rev Neurol 5: 649-658.
13. Shibata M, Ohtani R, Ihara M, Tomimoto H (2004) White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 35: 2598-2603.
14. Shibata M, Yamasaki N, Miyakawa T, Kalaria RN, Fujita Y, et al. (2007) Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke 38: 2826-2832.
15. Nakaji K, Ihara M, Takahashi C, Itohara S, Noda M, et al. (2006) Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke 37: 2816-2823.
16. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, et al. (2000) Highlevel neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058.
17. Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, et al. (2009) Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res 1294: 202-210.
18. Yamasaki N, Maekawa M, Kobayashi K, Kajii Y, Maeda J, et al. (2008) Alpha- CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain 1: 6.
19. Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, et al. (2007) Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53: 519-533.
20. Barnes CA (1979) Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol 93: 74-104.
21. Takao K, Toyama K, Nakanishi K, Hattori S, Takamura H, et al. (2008) Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol Brain 1: 11.
22. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
23. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357.
24. Deschaintre Y, Richard F, Leys D, Pasquier F (2009) Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73: 674-680.
25. Sun X, He G, Qing H, Zhou W, Dobie F, et al. (2006) Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103: 18727-18732.
26. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, et al. (2007) Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 282: 10873-10880.
27. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates betasecretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25: 10874-10883.
28. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
29. Akiyama H, McGeer PL (2004) Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 10: 117-118;author reply 118-119.
30. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30: 4845-4856.
31. Jankowsky JL, Xu G, Fromholt D, Gonzales V, Borchelt DR (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 62: 1220-1227.
32. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, et al. (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120: 701-713.
33. Arendash GW, Garcia MF, Costa DA, Cracchiolo JR, Wefes IM, et al. (2004) Environmental enrichment improves cognition in aged Alzheimer's transgenic mice despite stable beta-amyloid deposition. Neuroreport 15: 1751-1754.
34. Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 31: 454-463.
35. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
36. Mattson MP, Zhu H, Yu J, Kindy MS (2000) Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J Neurosci 20: 1358-1364.
37. Hemming ML, Selkoe DJ, Farris W (2007) Effects of prolonged angiotensinconverting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 26: 273-281.
38. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, et al. (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferatoractivated receptor gamma agonist. J Neurosci 28: 9287-9296.